Welcome to our dedicated page for Barinthus Biotherapeutics plc news (Ticker: vacc), a resource for investors and traders seeking the latest updates and insights on Barinthus Biotherapeutics plc stock.
Barinthus Biotherapeutics plc (NASDAQ: BRNS), formerly known as Vaccitech plc, is a clinical-stage biopharmaceutical company pioneering novel T cell immunotherapeutic candidates. The company emerged from the University of Oxford’s Jenner Institute, one of the oldest and most esteemed vaccine research centers in the world.
Barinthus Biotherapeutics specializes in leveraging proprietary T cell immunotherapeutic technologies to address chronic infectious diseases, cancer, and autoimmunity. Their innovative platform technologies, including ChAdOx, MVA, SNAP-TI, and SNAP-CI, enable the development of diverse therapeutic candidates.
Key products in their pipeline include:
- VTP-300: An investigational immunotherapeutic candidate aimed at providing a functional cure for chronic Hepatitis B virus (HBV) infection.
- VTP-200: A non-invasive treatment for persistent high-risk human papillomavirus (HPV).
- VTP-850: A T cell therapy designed for recurrent prostate cancer.
- VTP-1000: A preclinical candidate for celiac disease.
- VTP-1100: A preclinical cancer candidate targeting HPV-related cancers.
Recent updates include successful clinical milestones in HPV and HBV programs, highlighted by promising data from the Phase 1b/2a trial of VTP-300 presented at the European Association for the Study of the Liver (EASL). The company is also preparing to present further data at the upcoming AASLD Liver Meeting 2023.
Financially, Barinthus Biotherapeutics reported extending its cash runway into the second quarter of 2025, reflecting operational agility and efficiency. The company’s founders, Professor Adrian Hill and Professor Sarah Gilbert, bring substantial scientific and regulatory expertise to the team, bolstering their innovative pursuits.
Barinthus Biotherapeutics continues to evolve, drawing inspiration from the mythological navigator Barinthus, guiding the immune system towards healing. For more information, visit www.barinthusbio.com.
Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company, announced participation in key conferences this October. Notable events include the Maryland Life Sciences Bio Innovation Conference on October 3-4, where Dr. Geoffrey Lynn will discuss Emerging Vaccine Opportunities. Following this, the World Vaccine Congress in Barcelona from October 11-14 will feature Dr. Hugh Welles presenting a novel coronavirus vaccine approach. Other events include a virtual Hepatitis B Conference on October 18 and BIO-Europe in Leipzig from October 24-26.
Vaccitech plc (NASDAQ: VACC) has announced the promotion of Gemma Brown to Chief Financial Officer, succeeding Georgy Egorov. Brown, who joined the company in 2021, has been instrumental in financial reporting and corporate budgeting. CEO Bill Enright expressed confidence in her ability to ensure a smooth transition. Vaccitech focuses on developing novel immunotherapeutics and vaccines, including a COVID-19 vaccine co-invented with the University of Oxford, which is licensed to AstraZeneca.
Vaccitech plc (NASDAQ: VACC) announced the participation of CEO Bill Enright and CFO Georgy Egorov in two key investment conferences in New York City from September 12 to September 14, 2022. They will engage in a Fireside Chat at the Morgan Stanley 20th Annual Healthcare Conference on September 12, from 1:40 to 2:10 p.m. EDT, and present a Company Overview at the H.C. Wainwright 24th Annual Global Investment Conference on September 14 at 10:30 a.m. EDT. Investors can find additional details in the Events section of the company's website.
Vaccitech plc (NASDAQ: VACC) reported its Q2 2022 financial results, highlighting significant progress in its clinical trials and a robust financial performance. The company recognized $17.1 million in revenue from milestone and royalty payments linked to AstraZeneca's Vaxzevria® sales. Key clinical developments include interim data from its Phase 1b/2a trial of VTP-300, showing robust T-cell responses in chronic hepatitis B patients. The company ended Q2 with $192.3 million in cash, down from $214.1 million at the start of the year, and achieved a net income of $15.7 million for the quarter.
Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company, announced that CEO Bill Enright will participate in a fireside chat at the William Blair Biotech Focus Conference on July 11-12 in New York. Enright will also conduct one-on-one meetings with investors. The event's webcast will be available on the company's website starting at 9 a.m. EDT on July 11, with a replay accessible later. Vaccitech focuses on developing novel immunotherapies and vaccines to combat chronic infectious diseases, cancer, and autoimmunity.
Vaccitech plc (NASDAQ: VACC) provided an update on its clinical trial of VTP-300, showing promising results in patients with chronic hepatitis B. In a study involving 39 patients, VTP-300 as monotherapy or combined with low-dose nivolumab resulted in significant declines in Hepatitis B surface antigen (HBsAg), notably in patients with lower baseline levels. Durable reductions were observed, with some patients maintaining low HBsAg levels for up to eight months post-treatment. No serious adverse events were reported, indicating a favorable safety profile.
Vaccitech plc (NASDAQ: VACC) announced that CEO Bill Enright and CFO Georgy Egorov will participate in a fireside chat during the Jefferies Global Healthcare Conference on June 8, 2022, at 8:30 a.m. EDT in New York City.
A live webcast will be available on the Vaccitech website, with a replay following the event. Vaccitech is focused on developing novel immunotherapeutics and vaccines, notably for chronic infectious diseases and cancer, and co-invented a COVID-19 vaccine now licensed to AstraZeneca.
Vaccitech plc (NASDAQ: VACC) announced that CEO Bill Enright and CFO Georgy Egorov will present at the H.C. Wainwright Global Investment Conference on May 24, 2022, at 12:00 p.m. EDT. The event will take place in Miami and virtually, allowing broader participation. Interested parties can view a live webcast of the presentation on the Vaccitech website, with a replay available afterward. Vaccitech focuses on developing innovative immunotherapies and vaccines targeting chronic diseases and is known for co-developing a COVID-19 vaccine with the University of Oxford.
Vaccitech plc (NASDAQ: VACC) reported its financial results for Q1 2022, showcasing notable progress in its clinical programs. The company generated a net income of $2.6 million, translating to $0.07 per share, a significant recovery from a net loss of $15.4 million in Q1 2021. Cash and cash equivalents stood at $200.6 million, reflecting a decrease of $13.5 million. Research and development expenses rose to $10.7 million due to intensified development efforts on various candidates, while general and administrative expenses increased to $3.7 million. Upcoming milestones include interim efficacy data for VTP-300 and the initiation of a Phase 1/2 trial for VTP-850.
Vaccitech plc (NASDAQ: VACC) announced it will receive approximately $15 million in milestone and royalty payments from AstraZeneca's commercial sales of Vaxzevria® during Q4 2021. This payment marks a significant achievement for Vaccitech, as it is entitled to 24% of the payments received by Oxford University Innovation from AstraZeneca due to their exclusive licensing agreement. The company’s role in developing Vaxzevria® supports its financial strategy and expands its product portfolio, enhancing its position in the biopharmaceutical sector.
FAQ
What is the market cap of Barinthus Biotherapeutics plc (vacc)?
What does Barinthus Biotherapeutics specialize in?
What are the key products in Barinthus Biotherapeutics' pipeline?
Who founded Barinthus Biotherapeutics?
What recent clinical milestones has Barinthus Biotherapeutics achieved?
When will Barinthus Biotherapeutics present its latest data?
What is unique about Barinthus Biotherapeutics' platform technologies?
How has Barinthus Biotherapeutics evolved over time?
What is the significance of the name 'Barinthus Biotherapeutics'?
What is the financial outlook for Barinthus Biotherapeutics?
Where can more information about Barinthus Biotherapeutics be found?
